Skip to main content

Federal Register: notice

Guidance and Procedures for Implementing Tariff Adjustments for Specialty Pharmaceuticals and Associated Pharmaceutical Ingredients and Technical Corrections to the Harmonized Tariff Schedule of the United States for Duties Imposed Under Proclamation 11020

Federal Register published "Guidance and Procedures for Implementing Tariff Adjustments for Specialty Pharmaceuticals and Associated Pharmaceutical Ingredients and Technical Corrections to the Harmonized Tariff Schedule of the United States for Duties Imposed Under Proclamation 11020" on 2026-09-23. First seen on Kresmion 2026-10-26 18:24 UTC.

As of . Source: www.federalregister.gov. Method and limitations.

The record

Publisher
Federal Register
Agency
Commerce Department; Industry and Security Bureau
Source
Federal Register
Kind
Federal Register: notice
Jurisdiction
United States
Topics
Export controls, Trade
Importance
Headline, the top of three tiers Kresmion sets by fixed rules from the source's own fields
Published (source time)
2026-09-23 (the source gives a date only)
First seen on Kresmion
2026-10-26 18:24 UTC

The original

Open the original on www.federalregister.gov

Source: Federal Register (federalregister.gov). U.S. government work, public domain.

The publisher's summary

This notice defines the pharmaceutical products and lists the jurisdictions that are eligible to receive an ad valorem tariff rate of zero pursuant to Presidential Proclamation 11020 of April 2, 2026, "Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States," (Proclamation 11020). These pharmaceutical products include drugs and associated ingredients where all approved indications are designated as orphan; nuclear medicines; plasma derived therapies; fertility drugs; cell therapy product; gene therapy product; antibody drug conjugates; medical countermeasures related to chemical, biological, radiological, and nuclear threats; and animal health. Proclamation 11020 states that such products and associated ingredients receive the Section 232 zero tariff rate if they are products of a jurisdiction that has a current or forthcoming trade and security framework agreement or if they meet an urgent U.S. health need. This notice also includes procedures for the public to submit information for the Department of Commerce's (Commerce) approval to determine if imports of the pharmaceutical products and associated ingredients meet an urgent U.S. health need. This notice also issues five technical corrections to Annex I and one technical correction to Annex IV of the Proclamation.

The publisher's words, as published.

Federal Register document

Document number
2026-19498
Document type
Notice
Status
Published

Cite this data

Kresmion stores the publisher's own title, the source's time and the time Kresmion first saw it, and checks the primary link 1, 7 and 30 days after first sight. Kresmion adds no text of its own.

Upstream: Federal Register

Kresmion, "Guidance and Procedures for Implementing Tariff Adjustments for Specialty Pharmaceuticals and Associated Pharmaceutical Ingredients and Technical Corrections to the Harmonized Tariff Schedule of the United States for Duties Imposed Under Proclamation 11020", data as of 2026-09-23, https://kresmion.com/record/5828. Upstream data: Federal Register.

Link to this data (HTML):

<a href="https://kresmion.com/record/5828">Guidance and Procedures for Implementing Tariff Adjustments for Specialty Pharmaceuticals and Associated Pharmaceutical Ingredients and Technical Corrections to the Harmonized Tariff Schedule of the United States for Duties Imposed Under Proclamation 11020 (Kresmion)</a>